Biomarkers /
MYBL1
Overview
MYBL1 is altered in 1.02% of all cancers with colon adenocarcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, and invasive breast carcinoma having the greatest prevalence of alterations [3].
The most common alterations in MYBL1 are MYBL1 Amplification (0.34%), MYBL1 R654S (0.06%), MYBL1 N401S (0.05%), MYBL1 I150V (0.05%), and MYBL1 T479I (0.04%) [3].
Clinical Trials
Significance of MYBL1 in Diseases
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.